Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
Complete elimination of viral load in 100% of patients at day 7 vs 6% in…
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
Complete elimination of viral load in 100% of patients at day 7 vs 6% in…
Breckenridge Distillery Establishes March 31st as National Après Day
The World’s Highest Distillery Launches First Ever National Après Day in the U.S. and Celebrates #AprèsAnywhere…
Breckenridge Distillery Establishes March 31st as National Après Day
The World’s Highest Distillery Launches First Ever National Après Day in the U.S. and Celebrates #AprèsAnywhere…
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed…
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed…
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment…
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment…
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology…
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology…
Biomea Fusion Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA),…
Biomea Fusion Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA),…
Verizon continues to upgrade Fresno’s best network
Recent upgrades lead to testing results that show Verizon’s network is unbeaten in Fresno FRESNO,…
Verizon continues to upgrade Fresno’s best network
Recent upgrades lead to testing results that show Verizon’s network is unbeaten in Fresno FRESNO,…
Striim Achieves Google Cloud Ready – AlloyDB Designation
PALO ALTO, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Striim, Inc. announced today that it…
Striim Achieves Google Cloud Ready – AlloyDB Designation
PALO ALTO, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Striim, Inc. announced today that it…
Hypercharge to Supply 748 EV Charging Stations to Major Landmark Development in Surrey
Vancouver, British Columbia–(Newsfile Corp. – March 29, 2023) – Hypercharge Networks Corp. (NEO: HC) (OTCQB: HCNWF) (FSE:…
Hypercharge to Supply 748 EV Charging Stations to Major Landmark Development in Surrey
Vancouver, British Columbia–(Newsfile Corp. – March 29, 2023) – Hypercharge Networks Corp. (NEO: HC) (OTCQB: HCNWF) (FSE:…
Novel Therapeutic Solutions are Needed as Autism Rates Increase
Vancouver, British Columbia–(Newsfile Corp. – March 29, 2023) – Nova Mentis Life Science Corp. (CSE:…
Novel Therapeutic Solutions are Needed as Autism Rates Increase
Vancouver, British Columbia–(Newsfile Corp. – March 29, 2023) – Nova Mentis Life Science Corp. (CSE:…